| Code | CSB-RA011876MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody ASD-141, targeting ITGAM (Integrin Subunit Alpha M), also known as CD11b or complement receptor 3 alpha chain. ITGAM forms a heterodimer with ITGB2 (CD18) to create the Mac-1 receptor (αMβ2 integrin), which plays essential roles in leukocyte adhesion, migration, and phagocytosis. This integrin is predominantly expressed on myeloid cells including macrophages, monocytes, neutrophils, and natural killer cells, where it mediates cell-cell and cell-matrix interactions. ITGAM is critically involved in immune responses, inflammation, and complement-mediated processes, with dysregulation implicated in autoimmune diseases, chronic inflammatory conditions, atherosclerosis, and cancer progression.
ASD-141 is a research-oriented monoclonal antibody targeting ITGAM. Acting as an inhibitor of ITGAM, ASD-141 aims to block the inflammatory cell adhesion, migration and activation mediated by the αMβ2 integrin, thus being explored for the treatment of ischemia-reperfusion injury, autoimmune diseases, atherosclerosis and other inflammatory diseases driven by myeloid cells. This biosimilar provides researchers with a reliable tool for studying myeloid cell biology, inflammatory signaling pathways, and immune cell trafficking mechanisms. It supports investigations into leukocyte activation, adhesion molecule function, and the pathophysiology of inflammatory and immunological disorders.
There are currently no reviews for this product.